Table 2 Comparison of unadjusted and risk-adjusted outcomes by neutrophil-to-high density lipoprotein cholesterol ratio.
Outcomes | Events, n (%) | Unadjusted | Adjusted | ||
|---|---|---|---|---|---|
OR (95% CI) | P | OR (95% CI) | P | ||
Primary outcome | |||||
Deep Vein Thrombosis | 240 (9.3) | 1.98 (1.58–2.48) | < 0.001 | 1.69 (1.33–2.16) | < 0.001 |
Complications | |||||
Seizures | 65 (2.5) | 1.33 (0.91–1.95) | 0.141 | 1.39 (0.92–2.11) | 0.115 |
Acute Kidney Injury | 572 (22.1) | 2.42 (2.07–2.84) | < 0.001 | 1.84 (1.52–2.22) | < 0.001 |
Hospital-acquired infections | 1,192 (46.1) | 2.09 (1.86–2.35) | < 0.001 | 1.63 (1.43–1.86) | < 0.001 |
Pneumonia | 1,232 (47.7) | 2.46 (2.18–2.76) | < 0.001 | 2.03 (1.78–2.31) | < 0.001 |
Intracranial infection | 113 (4.4) | 3.41 (2.30–5.07) | < 0.001 | 2.28 (1.50–3.47) | < 0.001 |
Urinary tract infection | 364 (14.1) | 1.61 (1.35–1.92) | < 0.001 | 1.44 (1.19–1.74) | < 0.001 |
Bloodstream infection | 141 (5.5%) | 2.85 (2.05–3.98) | < 0.001 | 2.04 (1.44–2.91) | < 0.001 |
Mortality | |||||
Mortality at 30 days | 429 (27.6) | 2.27 (1.87–2.74) | < 0.001 | 1.50 (1.21–1.86) | < 0.001 |
Mortality at 90 days | 493 (31.7) | 2.28 (1.90–2.73) | < 0.001 | 1.50 (1.22–1.85) | < 0.001 |
Mortality at 180 days | 541 (34.7) | 2.31 (1.94–2.75) | < 0.001 | 1.58 (1.29–1.93) | < 0.001 |
Mortality at 1 year | 591 (38.0) | 2.21 (1.87–2.61) | < 0.001 | 1.56 (1.28–1.90) | < 0.001 |
Mortality at 2 years | 658 (42.3) | 2.06 (1.76–2.42) | < 0.001 | 1.46 (1.21–1.76) | < 0.001 |
Mortality at 3 years | 698 (44.8) | 2.02 (1.72–2.36) | < 0.001 | 1.46 (1.22–1.76) | < 0.001 |
Mortality at 4 years | 718 (46.1) | 1.90 (1.63–2.22) | < 0.001 | 1.40 (1.16–1.68) | < 0.001 |
Mortality at 5 years | 744 (47.8) | 1.88 (1.61–2.18) | < 0.001 | 1.40 (1.17–1.68) | < 0.001 |
In-hospital mortality | 294 (12.5) | 2.77 (2.21–3.47) | < 0.001 | 1.57 (1.22–2.02) | 0.001 |
Long-term mortality | 782 (50.2) | 1.83 (1.57–2.13) | < 0.001 | 1.41 (1.18–1.69) | < 0.001 |